Characterization of blood pressure and endothelial function in TRPV4- deficient mice with L-NAME-and angiotensin II-induced hypertension
被引:38
|
作者:
Nishijima, Yoshinori
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Wisconsin, Dept Med, Milwaukee, WI USA
Med Coll Wisconsin, Ctr Cardiovasc, Milwaukee, WI 53226 USAMed Coll Wisconsin, Dept Med, Milwaukee, WI USA
Nishijima, Yoshinori
[1
,2
]
Zheng, Xiaodong
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Wisconsin, Dept Med, Milwaukee, WI USA
Med Coll Wisconsin, Ctr Cardiovasc, Milwaukee, WI 53226 USAMed Coll Wisconsin, Dept Med, Milwaukee, WI USA
Zheng, Xiaodong
[1
,2
]
Lund, Hayley
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USAMed Coll Wisconsin, Dept Med, Milwaukee, WI USA
Lund, Hayley
[3
]
Suzuki, Makoto
论文数: 0引用数: 0
h-index: 0
机构:
Jichi Med Univ, Dept Pharmacol, Shimotsuke, Tochigi, JapanMed Coll Wisconsin, Dept Med, Milwaukee, WI USA
Suzuki, Makoto
[4
]
Mattson, David L.
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USAMed Coll Wisconsin, Dept Med, Milwaukee, WI USA
Mattson, David L.
[3
]
Zhang, David X.
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Wisconsin, Dept Med, Milwaukee, WI USA
Med Coll Wisconsin, Ctr Cardiovasc, Milwaukee, WI 53226 USAMed Coll Wisconsin, Dept Med, Milwaukee, WI USA
Zhang, David X.
[1
,2
]
机构:
[1] Med Coll Wisconsin, Dept Med, Milwaukee, WI USA
[2] Med Coll Wisconsin, Ctr Cardiovasc, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA
[4] Jichi Med Univ, Dept Pharmacol, Shimotsuke, Tochigi, Japan
Transient receptor potential vanilloid type 4 (TRPV4) is an endothelial Ca2+ entry channel contributing to endothelium-mediated dilation in conduit and resistance arteries. We investigated the role of TRPV4 in the regulation of blood pressure and endothelial function under hypertensive conditions. TRPV4-deficient (TRPV4(-/-)) and wild-type (WT) control mice were given L-NAME (0.5 g/L) in drinking water for 7 days or subcutaneously infused with angiotensin (Ang) II (600 ng/kg per minute) for 14 days, and blood pressure measured by radiotelemetry. TRPV4(-/-) mice had a lower baseline mean arterial pressure (MAP) (12-h daytime MAP, 94 +/- 2 vs. 99 +/- 2 mmHg in WT controls). L-NAME treatment induced a slightly greater increase in MAP in TRPV4(-/-) mice (day 7, 13 +/- 4%) compared to WT controls (6 +/- 2%), but Ang II-induced increases in MAP were similar in TRPV4(-/-) and WT mice (day 14, 53 +/- 6% and 37 +/- 11%, respectively, P < 0.05). Chronic infusion of WT mice with Ang II reduced both acetylcholine (ACh)-induced dilation (dilation to 10 +/- 5 mol/L ACh, 71 +/- 5% vs. 92 +/- 2% of controls) and the TRPV4 agonist GSK1016790A-induced dilation of small mesenteric arteries (10 +/- 8 mol/L GSK1016790A, 14 +/- 5% vs. 77 +/- 7% of controls). However, Ang II treatment did not affect ACh dilation in TRPV4(-/-) mice. Mechanistically, Ang II did not significantly alter either TRPV4 total protein expression in mesenteric arteries or TRPV4 agonist-induced Ca2+ response in mesenteric endothelial cells in situ. These results suggest that TRPV4 channels play a minor role in blood pressure regulation in L-NAME-but not Ang II-induced hypertension, but may be importantly involved in Ang II-induced endothelial dysfunction.